Drug Efficacy And SafetyPivotal Navepegritide data shows compelling efficacy with remarkable safety.
Market PotentialTransCon CNP could expand the market opportunity in ACH, with management estimating €1.5B in peak revenues, implying a 40% market share in the base case.
Regulatory ApprovalYorvipath has been granted orphan drug exclusivity by the FDA in patients with hypoparathyroidism, which provides 7 years of market exclusivity.